Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Antisense Pharma Changes Name to Isarna Therapeutics

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Development efforts focused on next generation oligonucleotides to treat cancer capitalizing on long-standing experience in TGF-ß.

Antisense Pharma GmbH has changed its name to Isarna Therapeutics GmbH and centralized all of its activities to a single location in Munich, the company announced today at the Sachs 13th Annual Biotech in Europe Investor Forum held in Zurich, Switzerland. The company’s new website is www.isarna-therapeutics.com.

“The name change to Isarna Therapeutics illustrates our new company dynamics combined with our continued leadership in the TGF-β pathway,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics.  “We are currently extending our pipeline to include next-generation oligonucleotides to treat cancer and expect several key near-term events that highlight this momentum.”

Isarna Therapeutics is committed to rapidly advancing a pipeline of next generation oligonucleotides (NGOs) targeting the various isoforms of TGF-β, a family of cytokine proteins that plays a significant role in cancer’s ability to escape immune system detection and promote tumor growth. Based on its unique deciphering of the TGF-β biology, the company has to date amassed an unmatched expertise in discovery and clinical development of oligonucleotides antagonists of the various TGF-β isoforms.  Much of this knowledge is the result of developing its first-generation compound trabedersen for several cancer indications and up to a Phase III clinical trial. The further development of that compound is focused on a Responder Patient Profiling Program (RPPP), aimed at assessing the genetic profile and responder biomarkers of patients suffering from cancer to establish correlations between tumor biology and response to anti-TGF-β oligonucleotides. This unique proprietary program will allow Isarna Therapeutics to select the right patients who will be best suited for treatment not only by trabedersen but also by any of the next generation of TGF-β inhibitors entering clinical development.

“Our goal as a company is to solidify our strengths in the TGF-β isoform family and remain a lean and focused organization capable of rapidly advancing compounds into mid-stage clinical development,” added Dr. Calais.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen
TGF-ß2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication.
Friday, October 05, 2012
Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma.
Tuesday, June 05, 2012
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Tuesday, May 15, 2012
Antisense Pharma Completes Round of Financing Worth Approximately 8 Million Euro
Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant.
Thursday, July 07, 2011
Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology
Antisense Pharma have announced that their international, randomized and active-controlled Phase IIb study G004-AP 12009, has been published in the official journal of the American Society for Neuro-Oncology (SNO).
Tuesday, November 02, 2010
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!